MTP18 as a prognostic biomarker and therapeutic target in lung adenocarcinoma
MTP18 functions as a novel oncogenic driver in LUAD by orchestrating a "fission-ROS-PI3K/AKT" signaling axis. Targeting MTP18-mediated mitochondrial dynamics offers a promising therapeutic strategy to disrupt both tumor growth and metabolic adaptation in LUAD.
Authors
- Youlang Zhou
- Yijie Tang (ORCID: https://orcid.org/0000-0003-0017-4476)
- Qixuan Li (ORCID: https://orcid.org/0000-0001-6618-3469)
- Han Su (ORCID: https://orcid.org/0009-0005-4957-6750)
- Jiahai Shi
- Tianyi Wang
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
Publication Details
- Journal
- Respiratory Research
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1186/s12931-026-03519-3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00